Storyline · business · 2 reports from 2 newsrooms
Tech slump lifts biopharma shares
First reported Oct 30, 11:27 AM ET · Latest Oct 30, 1:13 PM ET · Explainer updated Oct 30, 2:05 PM ET
That was this story from the latest newscast. Keep listening: the live channel Email me instead
Where things stand
US technology stocks dropped sharply amid concerns about AI costs, with Intel falling and the Nasdaq opening at its lowest in over two months, BBC News reports. At the same time, MarketWatch notes that large drugmakers such as Lilly, Gilead and Johnson & Johnson saw their shares climb to record highs.
The living record of this story: every fact with its status and source, updated as reporting comes in. Version 1, updated . Earlier versions
Facts
What the reporting says
Each fact is matched to the exact words of the report it comes from, and checked that those words really say it. Open one to see the source.
- Reported Biopharma stocks are the big winners of the tech wreck. Is this wrong?
Source
- “The big winners of the tech wreck are biopharma stocks.” — MarketWatch
- Reported US tech stocks have seen sharp falls over AI cost fears. Is this wrong?
Source
- “US tech stocks see sharp falls over AI cost fears.” — BBC News
- Reported Intel shares have continued to fall. Is this wrong?
Source
- “Shares in Intel have continued to fall” — BBC News
How to read the labels: Reported: one newsroom · Corroborated: two or more independent newsrooms · Confirmed: backed by a primary source such as an official release or filing · Disputed: newsrooms disagree · Updated: replaced by a newer figure. This story as data for AI assistants and developers.
Timeline
What changed: The tech market decline coincided with a rally in biopharma equities, pushing several big‑drug stocks to new peaks.
How this story developed
- New Biopharma stocks are the big winners of the tech wreck. US tech stocks have seen sharp falls over AI cost fears. Intel shares have continued to fall.
Every report, newest first
- The big winners of the tech wreck are biopharma stocks — MarketWatch
The shares of large drugmakers like Lilly, Gilead and J&J keep hitting record highs.
- US tech stocks see sharp falls over AI cost fears — BBC News
Shares in Intel have continued to fall while the tech-heavy Nasdaq opens at its lowest level in more than two months.
Questions
- It is unclear whether the biopharma rally will persist if tech pressures continue, or what specific factors are driving investor enthusiasm for drugmakers. Open
Ask this story
Answers come only from our reporting on this story, with the sources they rest on. If it doesn’t say, we’ll tell you. We keep the question’s text (never who asked) for 7 days so our anchors can answer common questions on air. Please don’t include personal details. Privacy
More: background
The Nasdaq is a stock index dominated by technology companies; a fall in its value signals broad weakness in the sector. Concerns that artificial‑intelligence projects may become too expensive can depress investor confidence in tech firms. Biopharma stocks represent companies that develop and sell medicines, and they often move independently of tech trends.
How this works: stories from different newsrooms are grouped by topic, then AI writes the explainer using only those reports. It may miss context the reports don't include.